Acute graft-versus-host disease (AGVHD) severity is usually graded (grades 0-IV) by the pattern of organ involvement using the classic Glucksberg-Seattle criteria (GSC). Recently, the International Bone Marrow Transplant Registry (IBMTR) developed a new Severity Index by regrouping the patterns of organ involvement into five Indexes (0-D) that appeared more predictive of transplant-related mortality (TRM) and transplant failure (TF, relapse or TRM). We studied the predictive value of both grading systems of TRM, TF and GVHDrelated mortality (GTRM) in a series of 114 consecutive patients у12 years old allografted from a histocompatible sibling at our institution, 100 of whom were evaluable for AGVHD. The IBMTR Severity Index showed better incremental prediction of TRM (relative risks (RR) of 1, 1.5, 1.4, 2 and 2.5 for Indexes 0, A, B, C and D), TF (RRs of 1, 1.6, 1.6, 2 and 2.3, respectively) and GTRM (RRs of 1, 2.2 and 4.8 for Indexes B, C and D) than the GSC. With the GSC different outcomes for TRM and TF were found only from grade 0 to I-II and 0 to IV or I-III to IV, but not from I-II to III. The GSC also appeared less predictive of GTRM (RRs of 1, 0.4 and 2.9 for grades II, III and IV). In our relatively small patient sample, the new IBMTR Severity Index appeared more predictive of transplant outcome than the GSC, especially between no AGVHD, early Indexes (A-B) and advanced Indexes (C-D). Keywords: stem cell transplantation; graft-versus-host disease; grading Moderate-to-severe acute GVHD (AGVHD) develops in 20-50% of adult recipients of an HLA-identical sibling allogeneic stem cell transplant (SCT). Mortality directly attributable to AGVHD or its treatment occurs in 10-20% of patients.
Moderate-to-severe acute GVHD (AGVHD) develops in 20-50% of adult recipients of an HLA-identical sibling allogeneic stem cell transplant (SCT). Mortality directly attributable to AGVHD or its treatment occurs in 10-20% of patients. [1] [2] [3] For classification and prognostic information, AGVHD has been graded according to the classic Glucksberg-Seattle criteria (GSC) for more than 20
Correspondence: Dr R Martino, Servei d'Hematologia Clínica, Hospital de la Santa Creu i Sant Pau, Av. Sant Antoni M a Claret, 167, 08025 Barcelona, Spain Received 30 November 1998; accepted 11 March 1999 years. 4, 5 Recently, the International Bone Marrow Transplant Registry (IBMTR) designed a new staging system from a large data set of adult patients receiving an HLAidentical sibling BMT. 6 This IBMTR Severity Index appeared more predictive of the risk of transplant-related mortality (TRM) and treatment failure (TF) than the GSC. We report the results of a comparative analysis of these two staging systems in patients allografted at our institution from an HLA-identical sibling over an 8-year period.
Materials and methods

Patients
From January 1990 to March 1998, 114 consecutive patients aged у12 years received an allogeneic SCT at our institution. Patient characteristics are shown in Table 1 . The median age was 36 years (range 12-58), and 68% of patients were male. GVHD prophylaxis consisted of CYA plus short-course MTX in 79%, CYA plus prednisone in 11% and CYA alone in 10%. CYA was given at 3 mg/kg/day i.v. started on day Ϫ1, which was later switched to the oral route with the aim of maintaining a trough whole blood concentration of 200-300 ng/mL. Short-course MTX consisted of 15 mg/m 2 on day ϩ1 and 10 mg/m 2 on days ϩ3, ϩ6 and ϩ11. The source of the stem cells was BM in 72% and PBSC in 28%. Partial T cell depletion of the graft was done in 20 cases (18%), with a final T cell content of 1-3 ϫ 10 5 /kg CD3 ϩ cells. 7, 8 One hundred patients survived у21 days with engraftment after transplant and were evaluable for this study.
Definition and grading of AGVHD
AGVHD was diagnosed clinically and confirmed by biopsy of affected tissues and/or postmortem histology. The nursing and medical records of all patients were reviewed by two BMT physicians (RM plus PR, MS or MB) to confirm the diagnosis, retrieve relevant data for the study and assign the maximum grade of AGVHD reached by both the GSC and the IBMTR Index, both based on the peak stage of skin, gut and liver involvement reached. Whenever there were discrepancies between both physicians, the records were reviewed together and a consensus was reached. Data were collected prospectively from January 1995 onward and retrospectively before this date. Early TRM (Ͻ21 days w/o engraftment) 14 12 Evaluable for acute GVHD (engrafted and alive у21 days) 100 88 MDS = myelodysplastic syndrome; AA = aplastic anemia; CML = chronic myelogenous leukemia; CLL = chronic lymphocytic leukemia; MM = multiple myeloma; CMV = cytomegalovirus; TBI = total body irradiation; CYA = cyclosporine; PDN = prednisone; MTX = methotrexate; SCT = stem cell transplantation; TRM = transplant-related mortality.
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a Includes chronic myelogenous leukemia in first chronic phase, acute leukemia in first remission and aplastic anemia.
Definitions
Endpoints were time to TRM, TF and AGVHD-related death. TRM was defined as death in patients without relapse, with censoring at relapse or last follow-up. TF was defined as death or relapse with patients alive without disease censored at time of last follow-up. GVHD-related mortality was defined as death directly attributable to progressive refractory AGVHD or death from an invasive infection during intensive immunosuppressive therapy for AGVHD or death from chronic extensive GVHD or an infection during its treatment.
Statistical methods
Relative risks (RR) of transplant outcomes were determined using Cox proportional hazards regression. Patients without AGVHD were the reference group for calculating the RR of TRM and TF with both staging systems. Acute GVHD entered the model as a time-dependent variable so that prior to onset the patient was considered in the reference group, and patients were censored at death or relapse. For calculating the RR of GVHD-related mortality, the rates observed in grades II and Index B were the reference values, since there were no AGVHD-related deaths in patients with early stages (0-I or 0-A, respectively) and only two deaths due to chronic GVHD (data not shown). RRs were calculated separately for the different grades/Severity Indexes, and differences in risk between categories were calculated using a Chi-square test.
9 Table 2 shows the observed incidence of AGVHD according to both staging systems. Thirty patients did not develop AGVHD. According to the GSC, the number of patients (and %) with grades I, II, III and IV AGVHD were 21, 25, 9 and 15, and with the IBMTR Index patients (and %) graded as A, B, C and D Severity Index were 11, 21, 22 and 16, respectively. As seen in Table 2 , the IBMTR Index tended to assign a higher overall grade for AGVHD severity than the GSC. Reclassification depended largely on the maximum extent of skin involvement. Thus, patients with GSC grade I were categorized as Index A or B depending on the extent of skin involvement (Ͻ25% or 25-50% of the body surface area (BSA), respectively), and patients with GSC grade II were classified as Index B or C if the rash affected 25-50% or у50% of the BSA. Patients with grade III AGVHD were categorized as Index C or D depending on the presence of stage 3 or 4 involvement in at least one organ, respectively, and 3/9 patients with GSC grade III were assigned an Index B because the maximum extent of rash was Ͻ50% of the BSA, with no stage 3 or 4 organ involvement. These were the only cases in which the grade assigned by the IBMTR Index was lower than the GSC. Table 3 shows the main clinical characteristics of the cases of AGVHD observed. Most patients (94%) had skin involvement, with gastrointestinal and/or liver involvement in 38%. The sequence of organ involvement followed the usual patterns, with skin followed by gastrointestinal in 28%, and followed by liver involvement in 10%. Seventy percent received systemic treatment with steroids, usually methylprednisolone at 2 mg/kg/day, at a median of 8 days from the first sign of AGVHD, and 15 patients received secondary treatment with antilymphocyte globulin at 15 mg/kg/day for 7 days. Sixteen patients died from progressive AGVHD or an invasive infection during intensive immunosuppression, while six died from chronic GVHD or an invasive infection during its treatment.
Results
Incidence of AGVHD according to GSC and IBMTR Index
Association between GSC and outcome
RRs (compared to patients without AGVHD) of TRM and TF by GSC grade are shown in Table 4 . Both RRs increased, although not significantly, from grade 0 to grades I and II, but the RR of both TRM and TF decreased from grade II to grade III. Patients with grade IV had a significantly higher risk of TRM and TF than those without AGVHD (P = 0.001 and 0.002, respectively). Table 4 shows the RRs of TRM and TF according to the IBMTR Index. As seen, patients with Indexes A/B, C and D AGVHD had progressively higher risks of both TRM Table 3 Characteristics of GVHD and TF, which were statistically significant for Indexes C and D with respect to Index 0. Table 5 shows the RRs of GVHD-related mortality according to both staging systems. As may be seen above, the RR for grade III was lower than for grade II, while it again significantly increased for grade IV (P = 0.001). However, with the IBMTR Index this RR progressively increased between Index B, C and D (P = 0.007 and P Ͻ 0.001 for B vs C and B vs D, respectively).
Association between IBMTR Index and outcome
Prediction of GVHD-related mortality
Discussion
The concept of modifying the GSC grading system for AGVHD to make it more objectively applicable and increase its association with transplant outcome was addressed at an international consensus conference. 10 The conference concluded that although the classic GSC distinguished patients with different risks of outcome, additional studies were needed to evaluate possible diversity of outcome within GVHD grades. The IBMTR performed such a study using registry data from 2129 adults receiving an HLA-identical sibling BMT and found that within different grades certain patterns of organ involvement had risks of outcome similar to other patterns from other grades. 6 Patterns with similar RRs were thus regrouped into four Severity Indexes, and the results were confirmed in a separate set of 754 T cell-depleted HLAidentical sibling BMT. Our overall incidence of grade II-IV AGVHD was 49%, which falls within the range of 20-50% reported in the literature. [1] [2] [3] 11 The pattern of organ involvement, and the primary and secondary treatments given were also those usually reported. [1] [2] [3] 11 We found that 30% of our patients had a shift in the AGVHD classification between both staging systems ( Table 2 ). These changes were from grade I to Index B (10/21 grade I), from grade II to Index C (17/25 grade II) and from grade III to Index B (3/9 grade III). Interestingly, very similar correlations between both systems have been recently reported by the Seattle team in a series of 838 adults and children who received an allogeneic BMT from an unrelated or related donor. 12 Thus, in this study the major changes were from grade I to Index B and grade II to Index C.
The most relevant finding in our study was that the predictability of TRM and TF was better with the IBMTR Index than with the GSC, mainly due to the fact that the RRs for both outcomes were similar for grades II and IV and were lower for grade III. With the IBMTR Index, however, the RRs progressively increased from Indexes A/B to C and D, thus having a better incremental correlation with transplant outcome. We also analyzed the correlation of both staging systems with the probability of dying from severe GVHD or its treatment (by an invasive infection), with similar results. Thus, the RR of GVHD-related death fell from grade II to III, while it showed a progressive increase from Index B to D.
Our study included patients transplanted from bone mar- row or peripheral blood stem cells and several approaches for GVHD prophylaxis. Despite this relative heterogeneity, the findings favoring the IBMTR Index for prediction of transplant outcome were significant. Of note, in the original report from the IBMTR, the predictive value of the Severity Index was confirmed in an independent group of T celldepleted BMT, suggesting that at least for HLA-identical sibling transplants the Index is useful for different GVHD prophylactic strategies. Possibly due to the few patients included within each IBMTR Index, we found that Indexes A and B had similar RRs of TRM and TF, a finding that was not found in the original report, in which both RRs significantly increased from A to B. 6 It is probably of greater clinical relevance, however, to identify different outcomes between moderateto-severe (grades III/IV or Indexes C/D) than between mild-to-moderate AGVHD (grades I/II or Indexes A/B), since the risks of TRM and TF increase mainly from mildto-moderate to moderate-to-severe stages. 1, 6, 11, 13 In this respect, the IBMTR Index appears to be more useful than the GSC.
It remains to be seen whether or not the IBMTR Index will be more predictive of transplant outcome than the GSC in other SCT settings, such as volunteer unrelated or family mismatched BMT or in a large series of sibling HLAidentical PBSCT. This latter study is currently underway within the PBSCT subcommittee of the Spanish Group of Hematopoietic Transplantation (GETH). Both classification systems are based on the peak severity of AGVHD involvement of skin, gut and liver. Recently, the Seattle team has proposed an alternative approach for AGVHD grading which places special emphasis on the overall clinical course as reflected by disease progression and response to treatment.
14 This novel approach may prove more predictive of outcome than the two static models since it includes clinically relevant parameters, and thus it should also be tested in future studies.
In summary, our results suggest that the outcome-based reclassification of patterns of organ involvement into new Severity Indexes may make the IBMTR Index more adequate for studying AGVHD after allogeneic HLAidentical sibling SCT due to its better correlation with transplant outcome than the classic GSC.
